MCL1 and neoplasm: To avoid potential side effects, we suggested the alternative use of DT2216, a PROTAC targeting BCL-xL for degradation in tumor cells but not in platelets [41, 50], and dinaciclib, a CDK9 inhibitor that potently suppresses MCL-1 [42, 44].